{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:41:41Z","timestamp":1790365301443,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP20K16397"],"award-info":[{"award-number":["JP20K16397"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00277-025-06189-1","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T22:44:09Z","timestamp":1737067449000},"page":"1047-1057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Topological importance of CD8+ T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma"],"prefix":"10.1007","volume":"104","author":[{"given":"Hiromichi","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-3804","authenticated-orcid":false,"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Nishimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"6189_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","volume":"6","author":"JM Connors","year":"2020","unstructured":"Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH et al (2020) Hodgkin lymphoma. Nat Rev Dis Primers 6:61","journal-title":"Nat Rev Dis Primers"},{"key":"6189_CR2","volume-title":"WHO classification of tumors 5th Edition Haematolymphoid Tumors Part B","author":"WHO Classification of Tumors Editorial Board","year":"2024","unstructured":"WHO Classification of Tumors Editorial Board (2024) WHO classification of tumors 5th Edition Haematolymphoid Tumors Part B. International Agency for Research on Cancer, Lyon"},{"key":"6189_CR3","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MGM Roemer","year":"2016","unstructured":"Roemer MGM, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H et al (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690\u20132697","journal-title":"J Clin Oncol"},{"key":"6189_CR4","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","volume":"3","author":"K Wienand","year":"2019","unstructured":"Wienand K, Chapuy B, Stewart C, Dunford AJ, Wu D, Kim J et al (2019) Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv 3:4065\u20134080","journal-title":"Blood Adv"},{"key":"6189_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V et al (2011) ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med 365:203\u2013212","journal-title":"N Engl J Med"},{"key":"6189_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A et al (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378:331\u2013344","journal-title":"N Engl J Med"},{"key":"6189_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","volume":"20","author":"RT Hoppe","year":"2022","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM et al (2022) NCCN Guidelines\u00ae insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Cancer Netw 20:322\u2013334","journal-title":"J Natl Compr Cancer Netw"},{"key":"6189_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319","journal-title":"N Engl J Med"},{"key":"6189_CR9","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P et al (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134:1144\u20131153","journal-title":"Blood"},{"key":"6189_CR10","first-page":"2187","volume":"141","author":"A Carbone","year":"2023","unstructured":"Carbone A, Gloghini A, Carlo-Stella C (2023) Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma. Blood 141:2187\u20132193","journal-title":"Blood"},{"key":"6189_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1369\/00221554211007793","volume":"69","author":"M Willemsen","year":"2021","unstructured":"Willemsen M, Krebbers G, Bekkenk MW, Teunissen MBM, Luiten RM (2021) Improvement of opal multiplex immunofluorescence workflow for human tissue sections. J Histochem Cytochem 69:339\u2013346","journal-title":"J Histochem Cytochem"},{"key":"6189_CR12","doi-asserted-by":"publisher","first-page":"13380","DOI":"10.1038\/s41598-017-13942-8","volume":"7","author":"ER Parra","year":"2017","unstructured":"Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Forget MA et al (2017) Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep 7:13380","journal-title":"Sci Rep"},{"key":"6189_CR13","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","volume":"130","author":"CD Carey","year":"2017","unstructured":"Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E et al (2017) Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420\u20132430","journal-title":"Blood"},{"key":"6189_CR14","first-page":"149","volume":"149","author":"J Lazarus","year":"2019","unstructured":"Lazarus J, Akiska Y, Perusina Lanfranca MP, Delrosario L, Sun L, Long D et al (2019) Optimization, design and avoiding pitfalls in manual multiplex fluorescent immunohistochemistry. J Vis Exp 149:149","journal-title":"J Vis Exp"},{"key":"6189_CR15","doi-asserted-by":"publisher","first-page":"e004114","DOI":"10.1136\/jitc-2021-004114","volume":"10","author":"T Zhang","year":"2022","unstructured":"Zhang T, Liu H, Jiao L, Zhang Z, He J, Li L et al (2022) Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL. J Immunother Cancer 10:e004114","journal-title":"J Immunother Cancer"},{"key":"6189_CR16","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1007\/s00262-021-02945-0","volume":"12","author":"AM Tsakiroglou","year":"2021","unstructured":"Tsakiroglou AM, Astley S, Dave M, Fergie M, Harkness E, Rosenberg A et al (2021) Immune infiltrate diversity confers a good prognosis in follicular lymphoma. Cancer Immunol Immunother 12:3573\u20133585","journal-title":"Cancer Immunol Immunother"},{"key":"6189_CR17","doi-asserted-by":"publisher","first-page":"e167629","DOI":"10.1172\/JCI167629","volume":"133","author":"MH Robinson","year":"2023","unstructured":"Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS et al (2023) Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. J Clin Invest 133:e167629","journal-title":"J Clin Invest"},{"key":"6189_CR18","doi-asserted-by":"publisher","first-page":"e002356","DOI":"10.1136\/jitc-2021-002356","volume":"9","author":"L Zhang","year":"2021","unstructured":"Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S et al (2021) Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. J Immunother Cancer 9:e002356","journal-title":"J Immunother Cancer"},{"key":"6189_CR19","doi-asserted-by":"publisher","first-page":"2066767","DOI":"10.1080\/2162402X.2022.2066767","volume":"11","author":"RD Gartrell","year":"2022","unstructured":"Gartrell RD, Enzler T, Kim PS, Fullerton BT, Fazlollahi L, Chen AX et al (2022) Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. Oncoimmunology 11:2066767","journal-title":"Oncoimmunology"},{"key":"6189_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12967-020-02469-8","volume":"18","author":"M Guo","year":"2020","unstructured":"Guo M, Yuan F, Qi F, Sun J, Rao Q, Zhao Z et al (2020) Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8\u2009+\u2009T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med 18:306","journal-title":"J Transl Med"},{"key":"6189_CR21","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00018-015-1835-0","volume":"72","author":"JC Nolz","year":"2015","unstructured":"Nolz JC (2015) Molecular mechanisms of CD8(+) T cell trafficking and localization. Cell Mol Life Sci 72:2461\u20132473","journal-title":"Cell Mol Life Sci"},{"key":"6189_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.coi.2010.02.005","volume":"22","author":"PS Kim","year":"2010","unstructured":"Kim PS, Ahmed R (2010) Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22:223\u2013230","journal-title":"Curr Opin Immunol"},{"key":"6189_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2013.08.013","volume":"264","author":"J Kmiecik","year":"2013","unstructured":"Kmiecik J, Poli A, Brons NHC, Waha A, Eide GE, Enger P\u00d8 et al (2013) Elevated CD3\u2009+\u2009and CD8\u2009+\u2009tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 264:71\u201383","journal-title":"J Neuroimmunol"},{"key":"6189_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/0008-5472.CAN-06-3388","volume":"67","author":"SJ Piersma","year":"2007","unstructured":"Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW et al (2007) High number of intraepithelial CD8\u2009+\u2009tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67:354\u2013361","journal-title":"Cancer Res"},{"key":"6189_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1080\/10428194.2016.1239263","volume":"58","author":"S Alonso-\u00c1lvarez","year":"2017","unstructured":"Alonso-\u00c1lvarez S, Vidriales MB, Caballero MD, Blanco O, Puig N, Martin A et al (2017) The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leuk Lymphoma 58:1144\u20131152","journal-title":"Leuk Lymphoma"},{"key":"6189_CR26","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/bloodadvances.2021006189","volume":"6","author":"K Karihtala","year":"2022","unstructured":"Karihtala K, Leivonen SK, Karjalainen-Lindsberg ML, Chan FC, Steidl C, Pellinen T et al (2022) Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv 6:1919\u20131931","journal-title":"Blood Adv"},{"key":"6189_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T et al (2010) Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med 362:875\u2013885","journal-title":"N Engl J Med"},{"key":"6189_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2010.031542","volume":"96","author":"P Kamper","year":"2011","unstructured":"Kamper P, Bendix K, Hamilton-Dutoit S, Honor\u00e9 B, Nyengaard JR, d\u2019Amore F (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin\u2019s lymphoma. Haematologica 96:269\u2013276","journal-title":"Haematologica"},{"key":"6189_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000321567","volume":"77","author":"A Tzankov","year":"2010","unstructured":"Tzankov A, Matter MS, Dirnhofer S (2010) Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 77:301\u2013308","journal-title":"Pathobiology"},{"key":"6189_CR30","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3109\/10428194.2011.580026","volume":"52","author":"LR Jakovic","year":"2011","unstructured":"Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MDP, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ (2011) The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 52:1913\u20131919","journal-title":"Leuk Lymphoma"},{"key":"6189_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hon.2295","volume":"35","author":"M Gotti","year":"2017","unstructured":"Gotti M, Nicola M, Lucioni M, Fiaccadori V, Ferretti V, Sciarra R et al (2017) Independent prognostic impact of tumour-infiltrating macrophages in early\u2010stage Hodgkin\u2019s lymphoma. Hematol Oncol 35:296\u2013302","journal-title":"Hematol Oncol"},{"key":"6189_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12916-016-0711-6","volume":"14","author":"B Guo","year":"2016","unstructured":"Guo B, Cen H, Tan X, Ke Q (2016) Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Med 14:159","journal-title":"BMC Med"},{"key":"6189_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1746-1596-7-12","volume":"7","author":"JA Harris","year":"2012","unstructured":"Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S (2012) CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 7:12","journal-title":"Diagn Pathol"},{"key":"6189_CR34","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3324\/haematol.2011.055459","volume":"97","author":"B S\u00e1nchez-Espiridi\u00f3n","year":"2012","unstructured":"S\u00e1nchez-Espiridi\u00f3n B, Martin-Moreno AM, Montalb\u00e1n C, Medeiros LJ, Vega F, Younes A et al (2012) Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin\u2019s lymphoma. Haematologica 97:1080\u20131084","journal-title":"Haematologica"},{"key":"6189_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3109\/10428194.2013.824079","volume":"55","author":"S Kayal","year":"2014","unstructured":"Kayal S, Mathur S, Karak AK, Kumar L, Sharma A, Bakhshi S et al (2014) CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma. Leuk Lymphoma 55:1031\u20131037","journal-title":"Leuk Lymphoma"},{"key":"6189_CR36","doi-asserted-by":"publisher","first-page":"9410","DOI":"10.1038\/s41598-020-66010-z","volume":"10","author":"L Werner","year":"2020","unstructured":"Werner L, Dreyer JH, Hartmann D, Barros MHM, B\u00fcttner-Herold M, Grittner U et al (2020) Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome. Sci Rep 10:9410","journal-title":"Sci Rep"},{"key":"6189_CR37","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood-2019-122535","volume":"134","author":"SS Patel","year":"2019","unstructured":"Patel SS, Weirather JL, Lipschitz M, Lako A, Chen PH, Griffin GK et al (2019) The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4\u2013positive T cells that are PD-1\u2013negative. Blood 134:2059\u20132069","journal-title":"Blood"},{"key":"6189_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","volume":"10","author":"T Aoki","year":"2020","unstructured":"Aoki T, Chong LC, Takata K, Milne K, Hav M, Colombo A et al (2020) Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma. Cancer Discov 10:406\u2013421","journal-title":"Cancer Discov"},{"key":"6189_CR39","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1200\/JCO.23.01115","volume":"42","author":"T Aoki","year":"2024","unstructured":"Aoki T, Jiang A, Xu A, Yin Y, Gamboa A, Milne K et al (2024) Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed\/refractory Hodgkin lymphoma. J Clin Oncol 42:1077\u20131087","journal-title":"J Clin Oncol"},{"issue":"9","key":"6189_CR40","first-page":"696","volume":"50","author":"The World Health","year":"2000","unstructured":"The World Health (2000) Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group Japanese Pathologists Pathol Int 50(9):696\u2013702","journal-title":"Lymphoma Study Group Japanese Pathologists Pathol Int"},{"key":"6189_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12185-016-2007-1","volume":"104","author":"S Makita","year":"2016","unstructured":"Makita S, Maruyama D, Maeshima AM, Taniguchi H, Miyamoto K, Kitahara H et al (2016) Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol 104:236\u2013244","journal-title":"Int J Hematol"},{"key":"6189_CR42","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/bjh.18762","volume":"201","author":"J Grund","year":"2023","unstructured":"Grund J, Iben K, Reinke S, B\u00fchnen I, Pl\u00fctschow HA, Meinhard BM et al (2023) Low B-cell content is associated with a CD73-low tumourmicroenvironment and unfavourable prognosis in classic Hodgkinlymphoma. Br J Haematol 201:1097\u20131102","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06189-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06189-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06189-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T07:35:03Z","timestamp":1743924903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06189-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6189"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06189-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4458312\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Nihon University Itabashi Hospital Clinical Research Judging Committee in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects (updated March 2023; approval number RK-210608-9). The committee waived the requirement for informed consent from the patients owing to the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"H.T. received honoraria from Chugai, Kyowa Kirin, Nippon Shinyaku, Takeda, and Bristol-Myers Squibbs. T.H. received honoraria from Bristol-Myers Squibb. M. N. received honoraria from Bristol-Myers Squibb. K.M. received honoraria from AstraZeneca, Chugai, Kyowa Kirin, Takeda, Bristol-Myers Squibb, Nippon Shinyaku, SymBio, and Ono Parma. H.N. has received research grants from MSD, Asahi Kasei Pharma, Astellas, AbbVie, Japan Blood Products Organization, Eisai, Otsuka Pharmaceutical, Ono Pharma, Kyowa Kirin, Sanofi, Shionogi, Daiichi Sankyo, Taiho, Takeda, Mitsubishi Tanabe, Chugai, Teijin Pharma, Eli Lilly, Nippon Kayaku, Nihon Pharmaceutical, Boehringer Ingelheim, and Pfizer. The authors declare no other conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}